The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib

BACKGROUND: Sorafenib included in Chinese medical insurance is the earliest targeted drug for radioactive iodine refractory differentiated thyroid cancer (RR-DTC). This study is to further demonstrate the clinical efficacy and safety of sorafenib used in Zhujiang Hospital of Southern Medical Univers...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Yuanna, Xiong, Xiaoli, Luo, Jiaxin, Zou, Quanliang, Chen, Pan, Pan, Liqin, Long, Man, Feng, Huijuan, Ouyang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393119/
https://www.ncbi.nlm.nih.gov/pubmed/37534207
http://dx.doi.org/10.3389/fendo.2023.1200932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393119/
https://www.ncbi.nlm.nih.gov/pubmed/37534207
http://dx.doi.org/10.3389/fendo.2023.1200932

Ejemplares similares